Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...
Company
NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems
The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...
NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...
HighTide Therapeutics Inc. Plans Hong Kong IPO to Fund Clinical Development
China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on...
Shanghai Duoning Biotechnology Partners with Wuhan Kaide Jinuo for Gene Therapy R&D
China’s Shanghai Duoning Biotechnology Co., Ltd has announced a strategic licensing deal with compatriot firm...
Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...
Novartis’s Iptacopan on Track for Priority Review Status in China for PNH Treatment
China’s Center for Drug Evaluation (CDE) website has indicated that Swiss pharmaceutical giant Novartis’ (NYSE:...
CSPC Pharmaceutical Group Partners with China Unicom for Digital Transformation
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a strategic partnership with Chinese mobile...
Novo Nordisk’s Semaglutide for Weight Loss Accepted for Review by China’s NMPA
Denmark-headquartered Novo Nordisk (NYSE: NVO) has announced that its market filing for the glucagon-like peptide-1...
Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage
Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...
CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment
Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...
Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...
Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G
Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...
CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome
China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...
Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC
China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...
Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development
Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series...
Akeso Biopharma’s Ebronucimab NDA Accepted for Review by China’s NMPA
China-based Akeso Biopharma (HKG: 9926) has announced that the National Medical Products Administration (NMPA) has...
Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion
US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which...
Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics
The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...
Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy
Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in...